Efficacy of an inactivated bivalent vaccine against the prevalent strains of Newcastle disease and H9N2 avian influenza

Table 2 Immune protection against NDV isolated in 2012–2014

Virus for challenge	Group	HI titer (log2)	Clinical signs/total	Deaths/total	Positive swabs/total	Positive swabs viral loading (EID₅₀/0.1 mL)	Protection rate (%)^a
NDV-HB12	A	7.7	0/10	0/10	1/10^b	<10^-1.00	90
NDV-HB12	D	0.0	5/5	5/5	5/5	10^-3.01	0
NDV-SD13	B	7.3	0/10	0/10	0/10	ND	100
NDV-SD13	E	0.0	5/5	5/5	5/5	10^-3.52	0
NDV-HB14	C	7.5	0/10	0/10	1/10	10^-1.07	90
NDV-HB14	F	0.0	5/5	5/5	5/5	10^-3.64	0
-	M	0.0	0/5	0/5	0/5^b,c	ND	100

ND no data
^aProtection definition: means survival without signs of clinical disease not shedding
^bCloaca swab
^cThroat swab

ISSN: 1743-422X